For US individuals 18 years and older

ONO-2808-03 MSA Study

Now Enrolling

Welcome to the
ONO-2808-03 Study!

We are now enrolling participants for the ONO-2808-03 MSA study.
This clinical trial aims to evaluate an investigational treatment for individuals diagnosed with
Multiple System Atrophy (MSA).

Find out if you could be eligible

ONO-2808 is an investigational drug therefore safety and efficacy have not been established.
ONO-2808 has not received regulatory approval for any use.

About this Study​

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system and movement.

This study seeks to better understand MSA and explore a potential treatment option for this serious disease.​

Active Study Sites

Could You Potentially be Eligible for the ONO-2808-03 MSA Study?

To participate in this study, here are some key eligibility criteria:

Symptom onset

less than 5 years

Diagnosed by a doctor

with MSA

Able to walk

(cane or walker OK) 10 ft and
back independently

Please note: There are other eligibility criteria in addition to the above key criteria.

Contact Us

If you have any questions or need further information, please do not hesitate to contact our support team at

Phone

1-800-717-3185

Email

OnoMSA@Syncorohealth.com

This website is intended for informational purposes and does not replace professional medical advice.

Always consult with your healthcare provider before making any healthcare decisions.

© 2024 ONO Pharma USA, Inc. All Rights Reserved.

Privacy Policy

You’re getting ready to leave the
ONO-2808-03 Study website

Thank you for visiting the ONO-2808-03 Study website. This link will take 
you to an external website.

Proceed to external website
No thanks, take me back to the ONO-2808-03 Study website.

Thank you for your interest in the 2808-03 Multiple System Atrophy --- MSA --- study recruitment effort.

We are pleased to share that we have successfully achieved our recruitment goals and are no longer seeking additional participants at this time. We appreciate your time and interest, and we wish you all the best.